These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2368472)

  • 1. [Polybrene thrombin time--a simple new method for monitoring a fibrinolytic therapy].
    Lutze G; Schraermeyer T; Töpfer G; Urbahn H
    Z Med Lab Diagn; 1990; 31(3):169-75. PubMed ID: 2368472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of plasma heparin by polybrene neutralization.
    Nash PV; Bjornsson TD
    Anal Biochem; 1984 May; 138(2):319-23. PubMed ID: 6742408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Which laboratory parameters are useful and necessary in fibrinolytic therapy?].
    Theiss W
    Klin Wochenschr; 1988; 66 Suppl 12():55-8. PubMed ID: 3347008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Measurement of fibrinogen in heparinized plasma using Polybrene].
    Watanabe M; Suzuki S; Kanayama M
    Rinsho Byori; 1983 Nov; 31(11):1235-8. PubMed ID: 6672296
    [No Abstract]   [Full Text] [Related]  

  • 5. The activator time. A method for control of activator activity during thrombolytic therapy.
    Blix S
    Scand J Haematol; 1969; 6(4):221-6. PubMed ID: 5388562
    [No Abstract]   [Full Text] [Related]  

  • 6. Thrombin time dilution test: a simple method for the control of heparin therapy.
    Pizzuto J; García-Méndez S; de-la-Paz Reyna M; Morales MR; Avilés A; Zavala B; Gaos C
    Thromb Haemost; 1979 Dec; 42(4):1276-85. PubMed ID: 542933
    [No Abstract]   [Full Text] [Related]  

  • 7. A new principle in heparin assaying based on partial neutralization of heparin with polybrene.
    Talstad I
    Thromb Res; 1980 May 1-15; 18(3-4):485-91. PubMed ID: 7414543
    [No Abstract]   [Full Text] [Related]  

  • 8. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
    Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
    Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of blood coagulation and fibrinolysis by polyamines in the presence of glycosaminoglycans.
    Homma R; Mase A; Toida T; Kashiwagi K; Igarashi K
    Int J Biochem Cell Biol; 2005 Sep; 37(9):1911-20. PubMed ID: 15936241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of extrinsic hemostasis activation by low-molecular-weight heparin.
    Stief TW
    Blood Coagul Fibrinolysis; 2006 Nov; 17(8):633-7. PubMed ID: 17102649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The assay of factor VIII: C in heparinized plasma: a polybrene neutralization method.
    Cumming AM; Wensley RT; Delamore IW
    Thromb Haemost; 1986 Feb; 55(1):58-60. PubMed ID: 3085265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of the antithrombin III-heparin-thrombin complex in the defense reaction of the anticoagulation system].
    Kudriashov BA; Liapina LA; Pastorova VE
    Vopr Med Khim; 1988; 34(2):38-42. PubMed ID: 3400189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Control of blood coagulation and complications in long-term streptokinase therapy].
    Schuster HP; Becker G; Prellwitz W; Weilemann LS; Schuster CJ
    Infusionsther Klin Ernahr; 1980 Oct; 7(5):260-70. PubMed ID: 7193187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monitoring heparin therapy by thrombin time and activated partial thromboplastin time--a comparison].
    Lang M; Fey MF; Furlan M; Beck EA
    Schweiz Med Wochenschr; 1986 Nov; 116(48):1681-4. PubMed ID: 3798064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Continuous heparin therapy in deep venous thrombosis and its monitoring with the Howel and thrombin times. Prospective study].
    Lozano Sánchez F; Almazán Enríquez A; Ramos Boyero M; del Villar Galán JL; Gómez Alonso A
    Angiologia; 1981; 33(5):272-82. PubMed ID: 7325396
    [No Abstract]   [Full Text] [Related]  

  • 16. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
    Hertfelder HJ; Bös M; Weber D; Winkler K; Hanfland P; Preusse CJ
    Semin Thromb Hemost; 2005; 31(4):426-40. PubMed ID: 16149021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Monitoring of heparin therapy using thrombin time and activated partial thromboplastin time--a comparison].
    Osterwalder J
    Schweiz Med Wochenschr; 1987 Apr; 117(14):539-40. PubMed ID: 3576165
    [No Abstract]   [Full Text] [Related]  

  • 18. Study of in vitro thrombin generation after neutralization of heparin.
    Hardy M; Douxfils J; Morimont L; Didembourg M; Carlo A; de Maistre E; Lecompte T; Mullier F
    Int J Lab Hematol; 2022 Feb; 44(1):168-176. PubMed ID: 34582127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Laboratory controls of heparin therapy with thrombin time, partial thromboplastin time and activated recalcification time].
    Lutze G; Presser HJ; Urbahn H
    Z Gesamte Inn Med; 1989 Apr; 44(8):235-40. PubMed ID: 2662657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of hexadimethrine bromide as a heparin-neutralizing agent in canine plasma.
    Green RA; LaFollette KA; Greig B
    Am J Vet Res; 1987 Mar; 48(3):496-8. PubMed ID: 3565907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.